Not finding it? Sign in to also search OpenAlex live.
-
Temporal patterns of immune-mediated adverse events (imAEs) with tremelimumab (T) plus durvalumab (D) in the phase 3 HIMALAYA study in unresectable hepatocellular carcinoma (uHCC).2023 Journal of Clinical Oncology conference-abstract Medicine Cancer Immunotherapy and Biomarkers Open access
George K.K. Lau, Bruno Sangro, Oxana Crysler, Wattana Sukeepaisarnjaroen, Oleg Nikolaevich Lipatov, Manabu Morimoto, +12 more
8citations
2 results